Literature DB >> 10199594

Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine.

T Niwa1, R Sato, Y Yabusaki, F Ishibashi, M Katagiri.   

Abstract

1. Aminopyrine N-demethylase activity was determined for 11 forms of human hepatic cytochrome P450s (P450s) expressed in yeast Saccharomyces cerevisiae and for human steroidogenic CYP17 expressed in Escherichia coli. 2. Among the hepatic P450s, the N-demethylation of aminopyrine was catalysed most efficiently by CYP2C19, followed by CYP2C8, 2D6, 2C18 and 1A2, whereas the activity with CYP2E1 was negligible. The kinetics of the N-demethylation process by CYP1A2, 2C8, 2C19 and 2D6 were studied by fitting to Michaelis-Menten kinetics by Lineweaver-Burk plots. CYP2C19 exhibited the highest affinity and a high capacity for the aminopyrine N-demethylation. CYP2C8 showed the highest Vmax, followed by CYP2C19, 2D6 and 1A2, whereas the Km for CYP2C8, 2D6 and 1A2 were 10-17 times higher than that for CYP2C19. Accordingly, the Vmax/Km for CYP2C19 was more than nine times higher than that of other P450s. 3. Human steroidogenic CYP17 also catalysed aminopyrine N-demethylation and the activity was comparable with that for CYP3A4 which is a dominant P450 in human liver. The activity was increased 1.5-fold by the addition of cytochrome b5, whereas the activity was not affected by the addition of Mg2+. 4. These results suggest that several human hepatic P450s, especially CYP2C19, and steroidogenic CYP17 exhibit aminopyrine N-demethylase activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199594     DOI: 10.1080/004982599238731

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.

Authors:  Jian Zhu-Ge; Ying-Nian Yu; Yu-Li Qian; Xin Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.

Authors:  Edoardo G Giannini; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 4.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

Review 5.  Insights into CYP2B6-mediated drug-drug interactions.

Authors:  William D Hedrich; Hazem E Hassan; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

Review 6.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

7.  Data on metabolic stability, aqueous solubility and CYP inhibition of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.

Authors:  Silvio Aprile; Ubaldina Galli; Gian Cesare Tron; Erika Del Grosso; Cristina Travelli; Giorgio Grosa
Journal:  Data Brief       Date:  2019-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.